The mere hint of potential legalization of marijuana in the U.S. is boosting the Canadian marijuana stock.
The medical device maker posted another solid quarter and has high hopes for product launches on the way.
The great news from a clinical study of experimental schizophrenia drug KarXT still has investors excited about the biotech stock.
Don't compare HEXO's latest disclosure about growing in an unlicensed area with CannTrust's issues. The scenarios are totally different.
Most analysts have become more negative about Aurora. Not Cantor Fitzgerald's Pablo Zuanic.
Last week's bad news continued to weigh on the beleaguered Canadian marijuana stock.
The clinical-stage biopharmaceutical company announced really great phase 2 results for its lead pipeline candidate.
In a week chock-full of losers, one Canadian cannabis producer appears to be the biggest loser of all.
Which stock wins in a matchup between these two cannabis-focused biotechs?
This biotech checks off all the boxes.
Which stock wins in a battle between these two retail pharmacy giants?
The Canadian cannabis producer had a dismal Q1. But don't throw in the towel on Aurora yet.
Which stock wins in a head-to-head matchup between these two big drugmakers?
Retired investors will especially like these reliable and solid dividend stocks.
Which stock wins in a one-on-one matchup between these two genomics revolution leaders?
The Canadian cannabis producer delivered much worse-than-expected fiscal 2020 first-quarter results.
Hint: There's an ongoing dispute that involves a significant chunk of money.
The Canadian cannabis producer appears to have pulled a rabbit out of the hat.
The negatives in the Q3 update are overshadowing the company's highest sales ever.
The Canadian cannabis producer had another terrible quarter. But if you look hard enough, there were a few things to like.